Diagnosis and Management of Gestational Trophoblastic Disease: A Comparative Review of National and International Guidelines
Abstract
Importance: Gestational trophoblastic disease (GTD) is associated with increased mortality and morbidity in women of reproductive age, if managed in a suboptimal way, left untreated, or diagnosed after the development of extensive metastases. Objective: The aims of this study were to review and compare the recommendations from published guidelines on these tumors of placental origin. Evidence Acquisition: A descriptive review of guidelines from the Royal College of Obstetricians and Gynecologists, the International Federation of Gynecology and Obstetrics, the European Society for Medical Oncology, and the Royal Australian and New Zealand College of Obstetricians and Gynecologists on GTD was carried out. Results: All the guidelines agree that suction evacuation is the optimal management for hydatidiform molar pregnancy and that chemotherapy, either single-agent (for low risk) or multiagent (for high risk), is the preferred treatment modality for choriocarcinoma. There is also a consensus that a future pregnancy should be avoided during follow-up; therefore, an effective contraception method should be used. All medical societies recommend the registration of such patients to GTD screening centers, endorse the use of International Federation of Gynecology and Obstetrics 2000 scoring system, and mention that the diagnosis of gestational trophoblastic neoplasia (GTN) should be based on the clinical presentation (from the genital tract and the metastatic sites) and the human chorionic gonadotropin evaluation. Additionally, all 4 medical societies recommend the surgical management of placental site trophoblastic tumors or epithelioid trophoblastic tumors, as chemotherapy is less effective in these cases. However, there is controversy regarding the appropriate follow-up after the treatment of hydatidiform mole, the administration of anti-D immunoglobulin, the time of oxytocin infusion, and the salvage regimens that may be used in cases of resistant or recurrent GTN. Conclusions: There is need for consistent international practice protocols, which will lead to an earlier diagnosis and eventually to a more effective management of GTD worldwide and decrease in the recurrence rate and in the associated morbidity and mortality. Target Audience: Obstetricians and gynecologists, family physicians. Learning Objectives: After participating in this activity, the learner should be better able to assess the diagnostic aspects of GTD; evaluate treatment options for hydatidiform mole and GTN; and describe the appropriate follow-up options for cases complicated with GTD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In cases of triploidy, the placenta presented with molar changes in approximately 16% of cases.
“Results from a study showed that in cases of triploidy, the placenta presented with molar changes in approximately 16% of cases [57,58].”
From First-Trimester Ultrasound: A Comparative Review of Guidelines (2026) · cites this paper as [58]
Cited by
Sorted by citations
First-Trimester Ultrasound: A Comparative Review of Guidelines
Boureka, E., Tsakiridis, I., Michos, G., Liberis, A., Giouleka, S., Mamopoulos, A., Kalogiannidis, I., & Dagklis, T. (2026) · Diagnostics · doi:10.3390/diagnostics16111695
Self-citation
- Authors
- Tsakiridis, I., Giouleka, S., Kalogiannidis, I., Mamopoulos, A., Athanasiadis, A., & Dagklis, T.
- Affiliations
- Clinical Fellow
- Resident Assistant
- Assistant Professor
- Aristotle University of Thessaloniki (GR)
- Corresponding author
- Tsakiridis, Ioannis
- ORCID
- Venue
- Obstetrical & Gynecological Survey
- Published
- 2020-12
- Volume
- 75
- Issue
- 12
- Pages
- 747-756
- ISSN
- 0029-7828 (ISSN-L)
- 1533-9866
- OpenAlex
- W3112911604
- Cited by
- 14
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 6 · 2021: 3
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrical & Gynecological Survey (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Gestational Trophoblastic Disease Studies
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- gestational trophoblastic disease, hydatidiform mole, choriocarcinoma, gestational trophoblastic neoplasia, placental site trophoblastic tumor, epithelioid trophoblastic tumor, suction evacuation, chemotherapy, anti-D immunoglobulin, oxytocin, treatment follow-up, human chorionic gonadotropin, salvage therapy
- MeSH terms
- Adult, Clinical Protocols, Female, Humans, International Cooperation, Patient Care Management, Pregnancy, Practice Guidelines as Topic, Gestational Trophoblastic Disease, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review